$NURO
NeuroMetrix, Inc.

2019 Form 10-K Financial Statement

#000162828020000575 Filed on January 28, 2020

View on sec.gov

Income Statement

Concept 2019 2018 Q4 2018
Revenue $9.273M $3.730M $16.09M
YoY Change -42.37% -24.34% -5.86%
Cost Of Revenue $7.027M $1.980M $8.707M
YoY Change -19.3% -30.77% -14.93%
Gross Profit $2.246M $1.750M $7.383M
YoY Change -69.58% -15.46% 7.67%
Gross Profit Margin 24.22% 46.92% 45.89%
Selling, General & Admin $10.68M $3.510M $14.54M
YoY Change -26.56% -13.97% -11.57%
% of Gross Profit 475.52% 200.57% 196.94%
Research & Development $3.102M $1.060M $5.135M
YoY Change -39.59% 20.45% 46.8%
% of Gross Profit 138.13% 60.57% 69.55%
Depreciation & Amortization $124.0K $0.00 $169.7K
YoY Change -26.93% -100.0% -35.31%
% of Gross Profit 5.52% 0.0% 2.3%
Operating Expenses $13.78M $4.570M $19.67M
YoY Change -29.96% -7.68% -1.33%
Operating Profit -$11.53M -$2.820M -$12.29M
YoY Change -6.16% -2.08% -6.05%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $7.762M $20.00K $60.00K
YoY Change 12836.16%
Pretax Income -$3.770M -$2.800M $20.00K
YoY Change -18950.0% -2.78% -100.16%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$3.773M -$2.800M $23.61K
YoY Change -16083.96% -2.78% -100.18%
Net Earnings / Revenue -40.69% -75.07% 0.15%
Basic Earnings Per Share -$3.90 $0.03
Diluted Earnings Per Share -$3.90 -$3.784M $0.02
COMMON SHARES
Basic Shares Outstanding 968.1K shares 7.365M shares 710.5K shares
Diluted Shares Outstanding 968.1K shares 1.389M shares

Balance Sheet

Concept 2019 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.130M $6.780M $6.780M
YoY Change -53.83% 67.82% 67.82%
Cash & Equivalents $3.130M $6.780M $6.780M
Short-Term Investments
Other Short-Term Assets $650.0K $860.0K $860.0K
YoY Change -24.42% -67.42% -67.42%
Inventory $1.160M $2.862M $2.860M
Prepaid Expenses
Receivables $300.0K $1.083M $1.080M
Other Receivables $190.0K $0.00 $0.00
Total Short-Term Assets $5.430M $11.59M $11.59M
YoY Change -53.15% 27.27% 27.36%
LONG-TERM ASSETS
Property, Plant & Equipment $1.430M $407.3K $2.380M
YoY Change -39.92% -7.6% 440.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $30.00K $30.00K $30.00K
YoY Change 0.0% -50.0% -50.0%
Total Long-Term Assets $1.460M $2.406M $2.400M
YoY Change -39.17% 385.17% 380.0%
TOTAL ASSETS
Total Short-Term Assets $5.430M $11.59M $11.59M
Total Long-Term Assets $1.460M $2.406M $2.400M
Total Assets $6.890M $13.99M $13.99M
YoY Change -50.75% 45.76% 45.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $730.0K $1.298M $1.300M
YoY Change -43.85% 77.02% 78.08%
Accrued Expenses $2.720M $1.659M $3.340M
YoY Change -18.56% -29.76% 10.23%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.450M $6.593M $6.590M
YoY Change -47.65% 43.89% 43.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $920.0K $1.300M $1.300M
YoY Change -29.23%
Total Long-Term Liabilities $920.0K $1.300M $1.300M
YoY Change -29.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.450M $6.593M $6.590M
Total Long-Term Liabilities $920.0K $1.300M $1.300M
Total Liabilities $4.360M $7.894M $7.890M
YoY Change -44.74% 72.29% 72.27%
SHAREHOLDERS EQUITY
Retained Earnings -$191.0M
YoY Change -0.17%
Common Stock $74.00
YoY Change -72.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.530M $6.098M $6.100M
YoY Change
Total Liabilities & Shareholders Equity $6.890M $13.99M $13.99M
YoY Change -50.75% 45.76% 45.73%

Cashflow Statement

Concept 2019 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$3.773M -$2.800M $23.61K
YoY Change -16083.96% -2.78% -100.18%
Depreciation, Depletion And Amortization $124.0K $0.00 $169.7K
YoY Change -26.93% -100.0% -35.31%
Cash From Operating Activities -$3.621M -$720.0K $2.862M
YoY Change -226.54% -77.29% -122.62%
INVESTING ACTIVITIES
Capital Expenditures $48.08K -$30.00K $143.6K
YoY Change -66.52% -66.67% -11.96%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$48.08K -$30.00K -$143.6K
YoY Change -66.52% -66.67% -11.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $15.11K 10.00K $18.62K
YoY Change -18.86% -99.7% -99.86%
NET CHANGE
Cash From Operating Activities -$3.621M -720.0K $2.862M
Cash From Investing Activities -$48.08K -30.00K -$143.6K
Cash From Financing Activities $15.11K 10.00K $18.62K
Net Change In Cash -$3.654M -740.0K $2.737M
YoY Change -233.52% -1025.0% 2794.62%
FREE CASH FLOW
Cash From Operating Activities -$3.621M -$720.0K $2.862M
Capital Expenditures $48.08K -$30.00K $143.6K
Free Cash Flow -$3.669M -$690.0K $2.718M
YoY Change -234.99% -77.6% -121.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 nuro Accrued Sales Return Provisions
AccruedSalesReturnProvisions
1101658 USD
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
043308180
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Local Phone Number
LocalPhoneNumber
890-9989
CY2019 dei Trading Symbol
TradingSymbol
NURO
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
4B Gill Street
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Woburn
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01801
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001289850
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1400674 shares
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity File Number
EntityFileNumber
001-33351
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q2 dei Entity Public Float
EntityPublicFloat
3893251 USD
CY2019 dei Entity Registrant Name
EntityRegistrantName
NeuroMetrix, Inc.
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei City Area Code
CityAreaCode
781
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q4 nuro Accrued Sales Return Provisions
AccruedSalesReturnProvisions
689000 USD
CY2019Q4 nuro Accrued Vacated Office Facility Costs
AccruedVacatedOfficeFacilityCosts
400000 USD
CY2018 nuro Allowance For Doubtful Accounts Charge
AllowanceForDoubtfulAccountsCharge
0 USD
CY2019 nuro Allowance For Doubtful Accounts Charge
AllowanceForDoubtfulAccountsCharge
49361 USD
CY2018 nuro Collaboration Income
CollaborationIncome
12255704 USD
CY2019 nuro Collaboration Income
CollaborationIncome
7716667 USD
CY2018Q4 nuro Collaborator Payments Receivable
CollaboratorPaymentsReceivable
0 USD
CY2019Q4 nuro Collaborator Payments Receivable
CollaboratorPaymentsReceivable
189008 USD
CY2018Q4 nuro Contract Manufacturer
ContractManufacturer
160000 USD
CY2019Q4 nuro Contract Manufacturer
ContractManufacturer
0 USD
CY2018 nuro Effective Income Tax Rate Reconciliation Impact Of Permanent Differences
EffectiveIncomeTaxRateReconciliationImpactOfPermanentDifferences
3.150
CY2019 nuro Effective Income Tax Rate Reconciliation Impact Of Permanent Differences
EffectiveIncomeTaxRateReconciliationImpactOfPermanentDifferences
-0.011
CY2019Q2 nuro Facility Relocation Costs
FacilityRelocationCosts
225000 USD
CY2019 nuro Facility Relocation Costs
FacilityRelocationCosts
100000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1082957 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
298967 USD
CY2018Q4 nuro Deferred Collaboration Income
DeferredCollaborationIncome
1956522 USD
CY2019Q4 nuro Deferred Collaboration Income
DeferredCollaborationIncome
0 USD
CY2018 nuro Effective Income Tax Rate Reconciliation382 Limitation
EffectiveIncomeTaxRateReconciliation382Limitation
0.000
CY2019 nuro Effective Income Tax Rate Reconciliation382 Limitation
EffectiveIncomeTaxRateReconciliation382Limitation
-8.615
CY2018Q4 us-gaap Accrued Advertising Current
AccruedAdvertisingCurrent
171000 USD
CY2019Q4 us-gaap Accrued Advertising Current
AccruedAdvertisingCurrent
68000 USD
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
62322 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1160448 USD
CY2019Q4 nuro Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Price Per Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePricePerShares
7.16
CY2018 nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
294264 USD
CY2019 nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
0 USD
CY2018Q4 nuro Technology Fees
TechnologyFees
450000 USD
CY2019Q4 nuro Technology Fees
TechnologyFees
450000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1298084 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
725658 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1659173 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1443574 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
391000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
454000 USD
CY2018Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
223756 USD
CY2018 nuro Idle Facility Impairment Charge
IdleFacilityImpairmentCharge
0 USD
CY2019 nuro Idle Facility Impairment Charge
IdleFacilityImpairmentCharge
400000 USD
CY2019Q4 nuro Income Tax Expense Benefit Attributable To Net Operating Loss Carry Forward
IncomeTaxExpenseBenefitAttributableToNetOperatingLossCarryForward
2500000 USD
CY2019Q4 nuro Income Tax Expense Benefit Attributable To Tax Credit Carry Forwards
IncomeTaxExpenseBenefitAttributableToTaxCreditCarryForwards
75000 USD
CY2018 nuro Increase Decrease In Collaboration Receivable
IncreaseDecreaseInCollaborationReceivable
0 USD
CY2019 nuro Increase Decrease In Collaboration Receivable
IncreaseDecreaseInCollaborationReceivable
189008 USD
CY2018 nuro Increase Decreasein Accrued Product Returns
IncreaseDecreaseinAccruedProductReturns
-856898 USD
CY2019 nuro Increase Decreasein Accrued Product Returns
IncreaseDecreaseinAccruedProductReturns
-412658 USD
CY2018 nuro Increase Decreasein Deferred Collaboration Income
IncreaseDecreaseinDeferredCollaborationIncome
1956522 USD
CY2019 nuro Increase Decreasein Deferred Collaboration Income
IncreaseDecreaseinDeferredCollaborationIncome
-1956522 USD
CY2019Q4 nuro Operating Lease Discount
OperatingLeaseDiscount
485485 USD
CY2019Q4 nuro Restricted Cash Collateral Letters Of Credit
RestrictedCashCollateralLettersOfCredit
226731 USD
CY2018 nuro Sales Revenue Goods Net Percentage From Foreign Country
SalesRevenueGoodsNetPercentageFromForeignCountry
0.12
CY2019 nuro Sales Revenue Goods Net Percentage From Foreign Country
SalesRevenueGoodsNetPercentageFromForeignCountry
0.13
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1231416 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
197114310 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
197319698 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
446077 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
446077 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
190331 USD
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
70000 USD
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
90136 shares
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
561654 shares
CY2018Q4 us-gaap Assets
Assets
13991880 USD
CY2019Q4 us-gaap Assets
Assets
6893686 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
11586165 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
5430814 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6780429 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3000000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3126206 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4043681 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6780429 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3126206 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2736748 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3654223 USD
CY2020Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
41627 shares
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
469213 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
738029 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1400674 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1400674 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
738029 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1400674 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9781755 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
978158 shares
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
74 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
140 USD
CY2019 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2018 us-gaap Cost Of Revenue
CostOfRevenue
8707082 USD
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
7026899 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35041300 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2208843 USD
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31239750 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1592993 USD
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
9158 USD
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-9455 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2599358 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
227843 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
222420 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
965191 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
96030 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35000000 USD
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35041300 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2200000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2208843 USD
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2018 us-gaap Depreciation
Depreciation
169712 USD
CY2019 us-gaap Depreciation
Depreciation
124012 USD
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
169712 USD
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
124012 USD
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.90
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.90
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
3.036
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
8.615
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.196
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.199
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-6.592
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
545459 USD
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4841278 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5923190 USD
CY2018 us-gaap Gross Profit
GrossProfit
7383056 USD
CY2019 us-gaap Gross Profit
GrossProfit
2245623 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
572153 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-572426 USD
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1319871 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-734629 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-408687 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-157644 USD
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
719303 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
897734 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-358661 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-243536 USD
CY2018 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
678100 shares
CY2019 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1094190 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
443505 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3621253 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
2861864 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
1163714 USD
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1767674 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
720209 USD
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
0 USD
CY2019Q2 us-gaap Inventory Write Down
InventoryWriteDown
1895884 USD
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
2595884 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
627732 USD
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
664098 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1990705 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
117431 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
641193 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
165785 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
165785 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
247347 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
653164 USD
CY2018Q4 us-gaap Liabilities
Liabilities
7894069 USD
CY2019Q4 us-gaap Liabilities
Liabilities
4363452 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13991880 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6893686 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6592897 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3446778 USD
CY2019Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
2500000 USD
CY2019Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
2300000 USD
CY2018 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
5766982 USD
CY2019 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1652171 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18618 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15106 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-143583 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48076 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2861713 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
23605 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-3773014 USD
CY2018 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
23605 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3773014 USD
CY2018 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
297858 USD
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018 us-gaap Operating Expenses
OperatingExpenses
19674623 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
13780334 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-12291567 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-11534711 USD
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
577460 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
588546 USD
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1301172 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
916674 USD
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
150000 shares
CY2019Q4 us-gaap Restructuring Reserve
RestructuringReserve
400000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1504864 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
407339 USD
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1968062 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1159774 USD
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.147
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
133580 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
333952 USD
CY2018 us-gaap Other Income
OtherIncome
59468 USD
CY2019 us-gaap Other Income
OtherIncome
45030 USD
CY2018 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
12315172 USD
CY2019 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
7761697 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
143583 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48076 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
860915 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
652919 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
30314 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
29650 USD
CY2018 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18618 USD
CY2019 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
15106 USD
CY2018Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
129837 USD
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
75300 USD
CY2018 us-gaap Profit Loss
ProfitLoss
23605 USD
CY2019 us-gaap Profit Loss
ProfitLoss
-3773014 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1567787 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
273448 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5134592 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3101976 USD
CY2019Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
11
CY2019Q2 us-gaap Restructuring Charges
RestructuringCharges
2345657 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-191016591 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194789605 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194800000 USD
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
16090138 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9272522 USD
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9698753 USD
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4755168 USD
CY2019Q2 us-gaap Severance Costs1
SeveranceCosts1
224773 USD
CY2019 us-gaap Severance Costs1
SeveranceCosts1
224773 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
446077 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
190331 USD
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.700
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.724
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.019
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
13086 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
34.54
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
10 shares
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
34420 shares
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.10
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.58
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
49410 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
164980 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
40.84
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.16
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
164980 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.16
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
19713.00
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
38.69
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.58
CY2018Q2 us-gaap Share Price
SharePrice
13.70
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
164980 shares
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y3M18D
CY2018Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
129837 USD
CY2019Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
75300 USD
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2017 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
USD
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
18618 USD
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
15106 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
5017389 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
6097811 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2530234 USD
CY2019Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 reverse stock split of its Common Stock
CY2019 us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1388557 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
968116 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
710457 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
968116 shares
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents in bank deposit accounts and trade receivables. The Company invests its funds in highly rated institutions and limits its investment in any individual account so that they do not exceed FDIC limits. The Company has not experienced significant losses related to cash and cash equivalents and does not believe it is exposed to any significant credit risks relating to its cash and cash equivalents.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, two customers accounted for </font><font style="font-family:inherit;font-size:10pt;">42%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">45%</font><font style="font-family:inherit;font-size:10pt;"> of accounts receivable, respectively. One customer accounted for </font><font style="font-family:inherit;font-size:10pt;">19%</font><font style="font-family:inherit;font-size:10pt;"> of revenues for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and two customers accounted for </font><font style="font-family:inherit;font-size:10pt;">23%</font><font style="font-family:inherit;font-size:10pt;"> of revenues, for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company relies on in-house assembly and four third-party manufacturers to manufacture the major portion of its current products and product components. The disruption or termination of the supply of these products or a significant increase in the cost of these products from these sources could have an adverse effect on the Company&#8217;s business, financial position, and results of operations.</font></div></div>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates and Assumptions</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances and regularly assesses these estimates, but actual results could differ materially from these estimates. Effects of changes in estimates are recorded in the period in which they occur.</font></div></div>

Files In Submission

Name View Source Status
0001628280-20-000575-index-headers.html Edgar Link pending
0001628280-20-000575-index.html Edgar Link pending
0001628280-20-000575.txt Edgar Link pending
0001628280-20-000575-xbrl.zip Edgar Link pending
a10k2019-2exhibit10134.htm Edgar Link pending
a10k2019ex231.htm Edgar Link pending
a10k2019exhibit10143.htm Edgar Link pending
a10k2019exhibit10162.htm Edgar Link pending
a10k2019exhibit10210.htm Edgar Link pending
a10k2019exhibit10211.htm Edgar Link pending
a10k2019exhibit10212.htm Edgar Link pending
a10k2019exhibit10213.htm Edgar Link pending
a10k2019exhibit1029.htm Edgar Link pending
a10k2019exhibit311.htm Edgar Link pending
a10k2019exhibit312.htm Edgar Link pending
a10k2019exhibit32.htm Edgar Link pending
a10k2019exhibit41.htm Edgar Link pending
a10k2019exhibit4313.htm Edgar Link pending
a10knuro20191231.htm Edgar Link pending
exhibit10210lsa12thmo_image1.gif Edgar Link pending
exhibit10212lsa14t_image1a01.gif Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
newexhibit10134sngoza_image1.jpg Edgar Link pending
newexhibit10143tthigg_image1.gif Edgar Link pending
newexhibit10143tthigg_image2.gif Edgar Link pending
newexhibit10143tthigg_image3.jpg Edgar Link pending
newexhibit10143tthigg_image4.gif Edgar Link pending
newexhibit10211lsa13t_image1.gif Edgar Link pending
newexhibit10213lsa15t_image1.gif Edgar Link pending
newexhibit1029lsa11th_image1.gif Edgar Link pending
newexhibit4313neurome_image1.gif Edgar Link pending
nuro-20191231.xml Edgar Link completed
nuro-20191231.xsd Edgar Link pending
nuro-20191231_cal.xml Edgar Link unprocessable
nuro-20191231_def.xml Edgar Link unprocessable
nuro-20191231_lab.xml Edgar Link unprocessable
nuro-20191231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending